Arkansas is currently home to 733 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: CHI St. Vincent, Arkansas, Little Rock, Arkansas
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Smart Checklist Implementation for Pediatric Tracheal Intubations in the ICU- Multicenter Study
NCT06085326
Recruiting
The purpose of the study is to implement a patient-provider dyad tailored, Electronic Health Record (EHR)-informed, digitized Smart Checklist as a Quality Improvement (QI) intervention to support bedside clinician teams to reduce Adverse Airway Outcomes (AAO) across 6 diverse pediatric intensive care units (ICUs).
Gender:
All
Ages:
19 years and below
Trial Updated:
11/07/2023
Locations: University of Arkansas, Little Rock, Arkansas
Conditions: Intubation Complication
Register for Updates
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
NCT05004129
Recruiting
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.
Gender:
All
Ages:
Between 6 years and 45 years
Trial Updated:
11/05/2023
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Congenital Myotonic Dystrophy
Register for Updates
Mindfulness in Hidradenitis Suppurativa
NCT06123429
Recruiting
The study will investigate the impact of an 8-week-long Mindfulness-Based Stress Reduction course on quality of life and disease severity in patients with hidradenitis suppurativa (HS).
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
11/02/2023
Locations: UAMS Dermatology Clinic, Little Rock, Arkansas
Conditions: Hidradenitis Suppurativa
Register for Updates
Barbershop Talk: Reducing Excessive Alcohol Consumption Among Black Men
NCT05609344
Recruiting
Socially disadvantaged Black men are at increased risk for unhealthy drinking habits that may, in turn, increase preventable chronic disease. This project seeks to test the effectiveness of a Screening, Brief Intervention, and Referral to Treatment (SBIRT) intervention for use within barbershop settings to reduce average drinking days and the number of unhealthy drinking days. Data from this study will further our understanding of how to reduce the risk of alcohol-related morbidity and mortality... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: UAMS, Little Rock, Arkansas
Conditions: Drinking Behavior, Drinking Excessive, Drinking
Register for Updates
Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne
NCT04582383
Recruiting
Acne is common illness of adolescents and young adults which is associated with substantial morbidity. While topical treatments are often sufficient for mild acne, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, hormonal therapies such spironolactone, and isotretinoin. Sebum overproduction is fundamental to the pathogenesis of acne with associated disordered keratinization and subsequent microbial colonization and inflammation resulting in the... Read More
Gender:
Female
Ages:
Between 16 years and 40 years
Trial Updated:
11/01/2023
Locations: Johnson Dermatology, Fort Smith, Arkansas
Conditions: Acne
Register for Updates
A Randomized, International Study to Assess the Safety of iTind Compared to UroLift
NCT04757116
Recruiting
The study objective is to demonstrate the safety of the iTind as compared to the UroLift.
Gender:
Male
Ages:
50 years and above
Trial Updated:
10/31/2023
Locations: Arkansas Urology, Little Rock, Arkansas
Conditions: Benign Prostatic Hyperplasia (BPH)
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-small cell lung carcinoma [NSCLC], triple-negative breast cancer [TNBC]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecte... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: University of Arkansas For Medical Sciences, Little Rock, Arkansas
Conditions: Solid Tumor
Register for Updates
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Recruiting
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/30/2023
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Pulmonary Embolism, Venous Thrombosis
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
Recruiting
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which... Read More
Gender:
All
Ages:
All
Trial Updated:
10/24/2023
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Plasma Cell Myeloma
Register for Updates
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
NCT05323734
Recruiting
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy. The study consists of a 4-week prospective Baseline phase, defined as the first 28 days following screening, followed by a double-blind phase consisting of a 4-week titration period (Day 1 to Day 28) and a 12-week maintenance period (Day 29 to Week 16).
Gender:
All
Ages:
Between 1 year and 65 years
Trial Updated:
10/18/2023
Locations: Arkansas Children's Research Institute, Little Rock, Arkansas
Conditions: Tuberous Sclerosis Complex
Register for Updates